Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells

BACKGROUND: PD-1/PD-L1 blockade can confer durable benefits in the treatment of metastatic cancers, but the response rate remains modest and potential adverse effects occur sometimes. Concentrating immunotherapeutic agents at the site of disease was believed to break local immune tolerance and reduc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Yang, Yuanyuan, Zhang, Xiaolong, Lin, Fangzhen, Xiong, Mengshang, Fan, Dongmei, Yuan, Xiangfei, Lu, Yang, Song, Yuewen, Zhang, Yizi, Hao, Mu, Ye, Zhou, Zhang, Yanjun, Wang, Jianxiang, Xiong, Dongsheng
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482514/
https://ncbi.nlm.nih.gov/pubmed/31023384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0723-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados